PD 0332991-d8 (Synonyms: Palbociclib-d8) |
カタログ番号GC40092 |
パルボシクリブ D8 (PD 0332991 D8) は、パルボシクリブと標識された重水素です。パルボシクリブは、選択的かつ経口的に活性な CDK4 および CDK6 阻害剤であり、IC50 はそれぞれ 11 および 16 nM です。 Palbociclib は、ER 陽性および HER2 陰性の乳がん研究の可能性を秘めています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1628752-83-9
Sample solution is provided at 25 µL, 10mM.
PD 0332991-d8 is intended for use as an internal standard for the quantification of PD 0332991 by GC- or LC-MS. PD 0332991 is an orally active, selective inhibitor of the cyclin D kinases Cdk4 (IC50 = 11 nM) and Cdk6 (IC50= 16 nM) with no activity against a panel of 36 additional protein kinases. It has been reported to have antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest at nanomolar concentrations. PD 0332991 can inhibit the growth of certain ER-positive or HER2-amplified breast cancer cells (IC50s as low as 4 nM) and demonstrates synergy with tamoxifen and trastuzumab, respectively. PD 0332991 inhibition of Cdk4 activity has been used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism that is independent of cell cycle progression.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *